



US 20210363226A1

(19) **United States**

(12) **Patent Application Publication**
He et al.

(10) **Pub. No.: US 2021/0363226 A1**

(43) **Pub. Date: Nov. 25, 2021**

(54) **RECOMBINANT COLLAGEN AND
RECOMBINANT COLLAGEN SPONGE
MATERIAL**

C08J 9/28 (2006.01)
C08J 9/36 (2006.01)
A61L 15/32 (2006.01)
A61L 15/42 (2006.01)

(71) Applicant: **Shaanxi Huikang Bio-Tech Co., Ltd.**,
Xi'an City (CN)

(52) **U.S. Cl.**
CPC *C07K 14/78* (2013.01); *C12N 1/145*
(2021.05); *C08J 9/28* (2013.01); *C12R*
2001/84 (2021.05); *A61L 15/325* (2013.01);
A61L 15/425 (2013.01); *C08J 9/36* (2013.01)

(72) Inventors: **Yue He**, Xi'an City (CN); **Jiuna Wang**,
Xi'an City (CN); **Jinli Zhao**, Xi'an
City (CN)

(21) Appl. No.: **17/367,212**

(57) **ABSTRACT**

(22) Filed: **Jul. 2, 2021**

The present disclosure provides a recombinant collagen and a recombinant collagen sponge material. The recombinant collagen comprises: (a) a protein composed of the amino acid sequence represented by SEQ ID NO: 2; and/or (b) a protein which has the same function as (a) and is derived from (a) by substitution, deletion and/or addition of one or more amino acids in SEQ ID NO:2. The recombinant collagen sponge material is obtained by sequential physical cross-linking and chemical cross-linking of the recombinant collagen. The recombinant collagen sponge material according to the present disclosure is capable of hemostasis, wound surface repair, moisture absorption and platelet aggregation, and has high moisture absorption, a significant hemostatic effect and good biocompatibility, assuming great clinical significance in the field of surgery.

Related U.S. Application Data

(63) Continuation of application No. PCT/CN2020/
108308, filed on Aug. 11, 2020.


Foreign Application Priority Data

Jan. 17, 2020 (CN) 202010052422.9

Publication Classification

(51) **Int. Cl.**
C07K 14/78 (2006.01)
C12N 1/14 (2006.01)

Specification includes a Sequence Listing.






FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8

RECOMBINANT COLLAGEN AND RECOMBINANT COLLAGEN SPONGE MATERIAL

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] An Application Data Sheet is filed concurrently with this specification as part of the present application. Each application that the present application claims benefit of or priority to as identified in the concurrently filed Application Data Sheet is incorporated by reference herein in its entirety and for all purposes.

SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which is submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jul. 1, 2021, is named SANYP012_Sequence_Listing.txt and is 10 KB in size.

TECHNICAL FIELD

[0003] The present disclosure relates to the technical field of medical technology and surgery, particularly relates to a recombinant collagen, a recombinant collagen sponge material, a method for preparation thereof, and use thereof, and more particularly to a recombinant collagen sponge material capable of hemostasis and wound surface repair, a method for preparation thereof, and use thereof.

BACKGROUND

[0004] In our daily lives there are many scenarios where uncontrolled bleeding is the main cause of sudden accidents and massive bleeding in medical operations, such as first-aid treatment for emergencies and hemostasis in trauma during surgery, and thus effective and rapid local hemostasis for patients is of particular importance. Therefore, shortening the hemostasis time of hemostatic materials and improving the quality of hemostasis has become an optimal strategy to reduce mortality among patients. Clinically commonly used hemostatic materials, such as cellulose-based hemostatic gauze, hemostatic fibers, and hemostatic bandages, have limitations in use, for example long hemostasis time, inability to treat wound infection and suppuration, and inability to induce regeneration in wounds. Therefore, a product having a superior hemostatic effect and an excellent tissue repairing effect is one of the clinical products urgently needed in the field of surgery.

[0005] CN101890179A provides a water-soluble hemostatic material which is mainly composed of oxidized regenerated cellulose ether, has a significant hemostatic effect but insufficient strength, is difficult to degrade in the body, and may be deposited in other organs of the human body after absorption.

[0006] CN104558675A provides a hemostatic microfibrous collagen sponge having a good hemostatic effect. However, it is difficult to ensure a controllable structure and quality of the product because only physical thermal cross-linking is applied, and there are also risks posed by immunogenicity and animal viruses.

[0007] CN103432620A provides an anti-adhesion hemostatic film mainly composed of dextran and prepared by electrospinning after cross-linking, the production process thereof is relatively complex, the cost is high, and the

biocompatibility, which is a strict requirement set upon clinical products, has not been evaluated.

SUMMARY

[0008] Due to the defects in the prior art, the first objective of the present disclosure is to provide a recombinant collagen; the second objective of the present disclosure is to provide a recombinant collagen sponge material having a hemostatic and wound surface repairing effect; the third objective of the present disclosure is to provide a method for preparing the recombinant collagen sponge material; and the fourth objective of the present disclosure is to provide use of the recombinant collagen sponge material as a hemostatic product in hemostasis and wound surface repair.

[0009] The objectives of the present disclosure are achieved through the following technical solutions.

[0010] In one aspect, the present disclosure provides a recombinant collagen, comprising:

[0011] (a) a protein composed of the amino acid sequence represented by SEQ ID NO: 2;

SEQ ID NO: 2

GPPGEPGNPGKPGSPGPAGSNGEPGPAGSPGEKGSQGSNGNPGPAGNQQGQ

PGNKGSPGNPGKPGEPGSGNPGQEPGSGQGNPGKNGQPGSPGSGSPGNQG

QPGKPGQPGEQGSPGNQGPAGNEGPKGQPGQNGKPGSPGPPGEPGNPGK

GSPGPAGSNGEPGPAGSPGEKGSQGSNGNPGPAGNQQGQPGNKGSPGNPGK

PGEPGSGNPGQEPGSGQGNPGKNGQPGSPGSGSPGNQGGQPGKPGQPGEQG

SPGNQGPAGNEGPKGQPGQNGKPGTGPDPGEPGNPGKPGSPGPAGSNGEP

GPAGSPGEKGSQGSNGNPGPAGNQQGQPGNKGSPGNPGKPGEPGSGNPGQGE

PGSQGNPGKNGQPGSPGSGQSPGNQGPQKPGQPGEQGSPGNQGPAGNEG

PKGQPGQNGKPG

and/or

[0012] (b) a protein which has the same function as (a) and is derived from (a) by substitution, deletion and/or addition of one or more amino acids in SEQ ID NO:2.

[0013] Based on the Gly-X-Y repeats of human type I collagen as the smallest repeating unit, the inventors creatively used the hydrophilic Gly-X-Y for permutation and combination, and designed a collagen with a length of 411 amino acids (represented by SEQ ID NO: 2). A corresponding nucleotide sequence (represented by SEQ ID NO:1) was also designed according to the codon preference in *Pichia*, synthesized, and inserted into the expression vector pPIC9K of *Pichia* to construct a pPIC9K-COL expression vector. The vector was transformed into a *Pichia* host strain GS115 by electrotransformation, high-copy number strains were picked through screening with the antibiotic G418, and finally a high-expression engineered strain of *Pichia* was obtained through shaking flask screening. This engineered strain was subjected to large-scale biological fermentation to obtain the raw material of the recombinant collagen. The recombinant collagen according to the present disclosure shows excellent cell attachment and hydrophilicity, and is an optimal raw material for preparing a recombinant collagen sponge material.

[0014] In another aspect, the present disclosure further provides a polynucleotide encoding the amino acid sequence

of the recombinant collagen above, and the DNA sequence of the polynucleotide comprises the DNA sequence represented by SEQ ID NO:1.

SEQ ID NO: 1

GGTCTCCCGGCGAACCAGGTAATCCTGGTAAACCTGGTTCCTCCCGGCC
 AGCTGGTTCACACGGGGAGCCGGTCTGCGCGCTCACCCGGAGAAAAGG
 GGTGCAAGGTAGTAATGGCAACCAGGACCGGCAGGGAATCAGGGTCAA
 CCTGGCAACAAGGAAGCCCGGGAATCCAGGTAAGCCGGGCGAGCCTGG
 ATCTAACGGGCCCCAGGGTGAACAGGCTCCAAGGAAATCCGGGGAAAA
 ACGGTACAGCTGGCTCACCCGGATCGCAAGGGAGTCCAGGTAATCAGGGC
 CAACCGGAAAGCCTGGGCAGCCCGGTGAGCAAGGCAGCCAGGAAACCA
 GGGGCCGGCGGTAAATGAAGGCCCTAAGGACAACCCGGGCAGAACGGTA
 AGCCAGGATCCCGGGTCTCCCGCGAACCAGGTAATCCTGGTAAACCT
 GGTTCCTCCCGCCAGCTGGTTCACACGGGGAGCCGGTCTGCGCGCTC
 ACCCGGAGAAAAGGGTTCGCAAGGTAGTAATGGCAACCAGGACCGGCAG
 GGAATCAGGGTCAACCTGGCAACAAGGAAGCCCGGGAATCCAGGTAAG
 CCGGCGAGCCTGGATCTAACGGGCCCCAGGGTGAACAGGCTCCAAGG
 AAATCCGGGAAAACGGTCAAGCTGGCTCACCCGGATCGCAAGGGAGTC
 CAGGTAATCAGGGCCAACCGGAAAGCCTGGGCAGCCCGGTGAGCAAGGC
 AGCCAGGAAACAGGGGCCGGCGGTAAATGAAGGCCCTAAGGACAACC
 CGGGCAGAACGGTAAGCCAGGTACCCAGGTCCTCCCGGCAACAGGTA
 ATCTGGTAAACCTGGTTCCTCCCGCCAGCTGGTTCACACGGGGAGCCG
 GGTCTGCGCGCTCACCCGAGAAAAGGGTTCGCAAGGTAGTAATGGCAA
 CCCAGGACCGGCAGGGAATCAGGGTCAACCTGGCAACAAGGAAGCCCG
 GGAATCAGGTAAGCCGGGCGAGCCTGGATCTAACGGGCCCCAGGGTGA
 CCAGGCTCCCAAGGAAATCCGGGGAAAACGGTCAGCCTGGCTCACCCGG
 ATCGCAAGGGAGTCCAGGTAATCAGGGCCAACCGGAAAGCCTGGGCGC
 CCGGTGAGCAAGGCAGCCAGGAAACAGGGGCCGGCGGTAAATGAAGGC
 CCTAAGGACAACCCGGGCAGAACGGTAAGCCA

[0015] In yet another aspect, the present disclosure further provides an expression vector containing the above-mentioned polynucleotide.

[0016] In yet another aspect, the present disclosure further provides a host strain containing the above polynucleotide, the host strain being an engineered *Pichia* strain that has been deposited (Date of deposit: Jan. 8, 2020; Depository authority: China General Microbiological Culture Collection Center (CGMCC); Address of depository authority: Institute of Microbiology Chinese Academy of Sciences, Building 3, No. 1 West Beichen Road, Chaoyang District, Beijing; Accession number: CGMCC No. 19314; Taxonomic name: *Pichia* sp.). The recombinant collagen according to the present disclosure is obtained by fermentation of the engineered *Pichia* strain.

[0017] In a further aspect, the present disclosure also provides a recombinant collagen sponge material, obtained by sequential physical cross-linking and chemical cross-linking of the aforementioned recombinant collagen;

wherein the recombinant collagen sponge material has a moisture absorption capacity of 40-50, and porosity of 90% or higher.

[0018] In the present disclosure, the moisture absorption capacity refers to the ratio of the weight of the recombinant collagen sponge material after water absorption to the weight of the recombinant collagen sponge material before water absorption. Porosity refers to the percentage of the pore volume in the recombinant collagen sponge material to the total volume of the recombinant collagen sponge material in its natural state.

[0019] The present disclosure achieves high porosity by low-degree cross-linking and freeze-drying techniques, as low-degree cross-linking (10%-20%) can ensure a good swelling property of the product, and freeze-drying can ensure uniform and stable pore distribution. The high water absorption according to the present disclosure is mainly determined by the designed amino acid sequence of the recombinant protein and the interconnected high porosity. Specifically, the designed amino acids increased the number of hydrophilic amino acids to improve water absorption, and the interconnected high porosity can provide water absorption and water retention.

[0020] In yet another aspect, the present disclosure provides a method for preparing the above-mentioned recombinant collagen sponge material, comprising the following steps

[0021] dissolving the aforementioned recombinant collagen in water to obtain a recombinant collagen solution;

[0022] lyophilizing the recombinant collagen solution by a freeze-drying method; and

[0023] subjecting the lyophilized and formed recombinant collagen to physical cross-linking and chemical cross-linking in sequence to obtain a recombinant collagen sponge material.

[0024] The recombinant collagen raw material according to the present disclosure is water-soluble, has excellent cell attachment property and hydrophilicity, has a low crosslinking degree after the physical crosslinking and chemical crosslinking to ensure the mechanical strength of the sponge while avoiding a risk of inflammation caused by prolonged retention of residual material in the body. After the low-degree cross-linking and freeze-drying process, a collagen sponge with good water absorption is obtained. The special amino acid sequence design improves the attachment of platelets, while the high water absorption can concentrate the platelets in the blood to rapidly stop bleeding.

[0025] Generally, by physical crosslinking alone it is difficult to obtain a uniform degree of crosslinking and the quality is uncontrollable, while chemical crosslinking alone often requires involvement of a high level of chemical crosslinking agents, which affects the biocompatibility of the final product. The present disclosure adopts the "physical plus chemical" cross-linking and can obtain a recombinant collagen sponge material having a low cross-linking degree and excellent biocompatibility.

[0026] In the above method, preferably, the recombinant collagen sponge material obtained after the cross-linkings is further subjected to washing, drying, and sterilization.

[0027] In the above method, preferably, the device used for the washing includes a rotating rod and a porous clamp box fixed on the rotating rod; wherein the porous clamp box is used to hold the recombined collagen sponge, and the

rotating rod is used to rotate and drive the porous clamp box to flip in a cleaning medium, so as to wash off the residual reagent in the recombinant collagen sponge material.

[0028] The washing device according to the present disclosure is an independently designed device, wherein the designed porous clamp box has an effect of fixing and shaping the recombined sponge, and the rotation of the rotating rod drives the clamp box to flip in a cleaning medium, which can improve the efficiency of washing off residual reagents in the recombined sponge. Due to the high efficiency of the washing device and the use of low-degree crosslinking agents, the biocompatibility of the product is ensured.

[0029] In the above method, preferably, the drying includes one or a combination of more of oven drying, freeze drying and vacuum drying.

[0030] In the above method, preferably, the sterilization is performed by 15 to 25 kGy Co⁶⁰ irradiation.

[0031] In the above method, preferably, the physical crosslinking includes one or a combination of more of thermal crosslinking, radiation crosslinking, and repeated freezing-reconstitution.

[0032] In the above method, preferably, the temperature for thermal crosslinking is 110° C., and the crosslinking duration is 2 h.

[0033] In the above method, preferably, the radiation source for the radiation cross-linking includes ultraviolet rays and/or gamma rays.

[0034] In the above method, preferably, the chemical crosslinking is performed by addition of a chemical crosslinking agent including one or a combination of more of glutaraldehyde, carbodiimide, and genipin.

[0035] In the above method, preferably, the concentration of the chemical crosslinking agent is 0.005 to 0.015 mol/L.

[0036] In the above method, preferably, the mass ratio of the chemical crosslinking agent to the recombinant collagen is 1:1 to 5.

[0037] After cross-linking, the recombinant collagen sponge material according to the present disclosure has a low degree of cross-linking of 10%-20%, as determined by percentage analysis of free amino groups on the side chains of amino acids.

[0038] In the above method, preferably, the chemical crosslinking duration is 1 to 5 hours.

[0039] In the above method, preferably, the concentration of the recombinant collagen solution is 1% to 5%.

[0040] In the above method, preferably, before freeze-drying the recombinant collagen solution, it further includes injecting the recombinant collagen solution into a mold for forming.

[0041] In the above method, preferably, the recombinant collagen solution is freeze-dried at a gradient from -50° C. to 30° C.

[0042] In another aspect, the present disclosure further provides use of the above-mentioned recombinant collagen sponge material as a hemostatic product in hemostasis and wound surface repair. It is mainly applicable in the field of medical surgery, for hemostasis of acute and chronic wounds during surgeries and tissue repair at wound surfaces.

[0043] The recombinant collagen raw material according to the present disclosure is water-soluble, shows excellent cell attachment property and hydrophilicity, and provides a collagen sponge having good water absorption after being subjected to low-degree cross-linking and freeze-drying

processes. The high efficiency of the washing device and use of a low-degree crosslinking agent ensure the biocompatibility of the product. The special amino acid sequence design improves the platelet attachment ability, and the high water absorption can concentrate the platelets in the blood so as to quickly stop bleeding. In summary, the recombinant collagen sponge material according to the present disclosure is capable of hemostasis, wound surface repair, moisture absorption and platelet aggregation, and has high moisture absorption, a significant hemostatic effect and good biocompatibility, assuming great clinical significance in the field of surgery.

DESCRIPTION OF DRAWINGS

[0044] FIG. 1 shows the results of an electrophoresis of protein expression levels in different strains according to the present disclosure.

[0045] FIG. 2 is a schematic representation of the structure of the washing device used in an example of the present disclosure.

[0046] FIG. 3 shows a comparative experiment of cell proliferation in the recombinant collagen sponge material in an example of the present disclosure.

[0047] FIG. 4 shows a comparative experiment of hemostatic performance of the recombinant collagen sponge material on a New Zealand rabbit liver over 20 seconds in an example of the present disclosure.

[0048] FIG. 5 is a schematic representation of a wound surface model on the back of a rat in an example of the present disclosure.

[0049] FIG. 6 shows the repairing of wound surfaces with the materials in various groups at different time points in an example of the present disclosure.

[0050] FIG. 7 shows a liquid chromatography profile for a compositional analysis of the amino acid components of the recombinant collagen in an example of the present disclosure.

[0051] FIG. 8 is a mass spectrometry profile of the molecular weight of the recombinant collagen in an example of the present disclosure.

DEPOSITION OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURES

[0052] The engineered *Pichia* strain according to the present disclosure:

[0053] Date of deposit: Jan. 8, 2020;

[0054] Depository authority: China General Microbiological Culture Collection Center (CGMCC);

[0055] Address of depository authority: Building 3, No. 1 West Beichen Road, Chaoyang District, Beijing;

[0056] Accession number: CGMCC No. 19314;

[0057] Taxonomic name: *Pichia* sp.

DETAILED DESCRIPTION OF INVENTION

[0058] In order to provide a clearer understanding of the technical features, objectives and beneficial effects of the present disclosure, the technical solutions of the present disclosure will be described in detail below, but are not to be construed as limiting the implementable scope of the present disclosure.

[0059] The recombinant collagen raw material used in the following examples was obtained by constructing a genetically engineered strain, producing a recombinant collagen

having a molecular weight of 38 kDa by microbial fermentation, purifying and then freeze-drying the recombinant collagen.

[0060] The specific process was as follows.

[0061] Based on the Gly-X-Y repeats of human type I collagen as the smallest repeating unit, the inventors creatively used the hydrophilic Gly-X-Y for permutation and combination, and designed a collagen with a length of 411 amino acids (represented by SEQ ID NO: 2). A corresponding nucleotide sequence according to the codon preference in *Pichia* (represented by SEQ ID NO:1) was also designed, synthesized, and inserted into the expression vector pPIC9K of *Pichia* to construct a pPIC9K-COL expression vector. The vector was transformed into a *Pichia* host strain GS115 by electrotransformation, high-copy number strains were picked through screening with increasing concentrations of Geneticin G418 in the medium, transformants with a high copy number were picked for an expression test in shaking flasks, and strains showing a high level of expression were selected as the genetically engineered strain for production. Under the same electrophoresis conditions, the strain B31 showed a relatively high expression level (as shown in FIG. 1), and was deposited as an engineered strain (accession number: CGMCC No. 19314) for scale-up production. The engineered strain was used to carry out large-scale biological fermentation to obtain the raw material of the recombinant collagen.

[0062] The process of obtaining the recombinant collagen by fermenting the engineered strain according to the present disclosure was as follows.

(1) Primary Seed Cultivation

[0063] The engineered strain of the present disclosure (Accession number: CGMCC No. 19314) was inoculated into an Erlenmeyer flask containing a BMGY medium, and incubated in a thermostatic culturing shaker at 29° C., 225 rpm for 60 to 70 hours to obtain a primary seed liquid.

(2) Secondary Seed Cultivation

[0064] The primary seed liquid was fed into a seed tank, and then cultured in the tank at a temperature controlled at 29.0±1.0° C., a tank pressure of 0.050±0.010 MPa, and pH 5.0. During the culturing, the aeration and stirring speed were adjusted to maintain the dissolved oxygen at about 30%. The secondary seed cultivation was performed for about 16 hours to obtain a secondary seed liquid.

(3) Fermentation in Fermenter

Base Material Cultivation Stage

[0065] After the secondary seed cultivation was complete, the secondary seed liquid was transferred to a fermenter, the culturing temperature was controlled at 29.0±1.0° C., the tank pressure was controlled at 0.050±0.010 MPa, and the DO was controlled at about 30% by manual adjustment of the aeration, oxygen level and rotation speed. After 12 to 18 hours of cultivation, the feeding cultivation stage started.

Glycerin Feeding Stage

[0066] When the feeding stage started, the oxygen supply was immediately turned off, and the DO was lowered to about 40% by reducing the stirring speed. An automatic feeding system was started with an initial flow rate of a

glycerin solution of 0.8 mL/min (1 s/60 s). After 12 hours of feeding, a sample was taken to measure the wet strain weight of the fermentation broth. When the wet strain weight of the fermentation broth reached 200 g/L, the glycerin feeding was stopped and starvation was started.

Starvation Stage

[0067] The DO was controlled at 30-40% by adjusting the aeration volume and reducing the stirring speed, and the starvation state was maintained for 1.0 h.

Methanol Induction Stage

[0068] The methanol flow rate was increased according to the actual DO. The methanol flow rate was generally controlled within 8.0 mL/min (10 s/60 s), and the methanol induction duration was generally controlled at 40 to 48 h. The DO during methanol induction should be controlled at 20 to 35%, and it should be confirmed that no excessive methanol was accumulated at this stage.

Discharge from Fermenter

[0069] After induction for 44 to 48 hours, the recombinant collagen was discharged from the fermenter, harvested, and sampled for testing.

[0070] The amino acid sequence of the recombinant collagen is represented by SEQ ID NO: 2:

SEQ ID NO: 2

GPPGEPGNPGKPGSPGAGSNGEPGPAGSPGEGKSGSNGNPGPAGNQQG
 PGNKSGPNPGKPGEPGSGNPGQEGPESQGNPGKNGQPGSPGSQSGPNQG
 QPGKPGQPGEGQSGPNQGPAGNEGPKGQPGQNGKPGSPGPPGEPGNPGK
 GSPGAGSNGEPGPAGSPGEGKSGSNGNPGPAGNQQGQPGNKGSPGNPGK
 PGEPGSGNPGQEGPESQGNPGKNGQPGSPGSQSGPNQGGQPGKPGQPGEGQ
 SPGNQGPAGNEGPKGQPGQNGKPGTGPFPGEPGNPGKPGSPGAGSNGEP
 GPAGSPGEGKSGSNGNPGPAGNQQGQPGNKGSPGNPGKPGEPGSGNPGQGE
 PGSQGNPGKNGQPGSPGSQSGPNQGGQPGKPGQPGEGQSGPNQGPAGNEG
 PKGQPGQNGK

[0071] The recombinant collagen according to the present disclosure shows excellent cell attachment property and hydrophilicity, and is an optimal raw material for preparing a recombinant collagen sponge material.

[0072] The washing device used in the following Examples was shown in FIG. 2. The washing device includes a rotating rod and a porous clamp box fixed on the rotating rod; wherein the porous clamp box is used to hold the recombinant collagen sponge, and the rotating rod is used to rotate and drive the porous clamp box to flip in a cleaning medium, so as to wash off residual reagents in the recombinant collagen sponge material.

Example 1

[0073] This Example provides a recombinant collagen sponge material and a method for preparation thereof. The method comprised:

[0074] (1) preparing a 3% solution of a recombinant collagen (molecular weight: 38 kDa) and stirring it thoroughly; pouring the recombinant collagen solution into a mold for forming, and lyophilizing it by a freeze-drying

method with the following lyophilization parameters: -50°C . for 5 h, -30°C . for 3 h, -20°C . for 3 h, -10°C . for 2 h, 0°C . for 1 h, 10°C . for 5 h, 20°C . for 20 h, 30°C . for 60 h;

[0075] (2) performing physical crosslinking with ultraviolet radiation at a radiation distance of 20 cm for 6 h, and then performing chemical crosslinking with 0.01 mol/L carbodiimide (the mass ratio of carbodiimide to recombinant collagen was 1:1) at a reaction temperature of 4°C . for 5 h;

[0076] (3) washing in the washing device according to the present disclosure 5 times, with 20 minutes each time;

[0077] (4) drying the washed recombinant collagen sponge at a temperature of 60°C . for 3 hours; encapsulating a sample thereof and sterilizing it with 15 kGy Co^{60} irradiation to obtain a recombinant collagen sponge material.

Example 2

[0078] This Example provides a recombinant collagen sponge material and a method for preparation thereof. The method comprised:

[0079] (1) preparing a 5% solution of a recombinant collagen (molecular weight: 38 kDa) and stirring it thoroughly; pouring the recombinant collagen solution into a mold for forming, and lyophilizing it by a freeze-drying method with the following lyophilization parameters: -50°C . for 6 h, -30°C . for 2 h, -20°C . for 2 h, -10°C . for 2 h, 0°C . for 2 h, 10°C . for 10 h, 20°C . for 20 h, 30°C . for 50 h;

[0080] (2) performing physical crosslinking at a high temperature of 110°C . for 2 h, and then performing chemical crosslinking with a 0.005 mol/L solution of genipin (the mass ratio of genipin to recombinant collagen was 1:4) at a reaction temperature of 25°C . for 2 h;

[0081] (3) washing in the washing device according to the present disclosure 6 times, with 15 minutes each time;

[0082] (4) freeze-drying the washed recombinant collagen sponge with the same lyophilization parameters as in the first washing; encapsulating a sample thereof and sterilizing it with 25 kGy Co^{60} irradiation to obtain a recombinant collagen sponge material.

Example 3

[0083] This Example provides a recombinant collagen sponge material and a method for preparation thereof. The method comprised:

[0084] (1) preparing a 1% solution of a recombinant collagen (molecular weight: 38 kDa) and stirring it thoroughly; pouring the recombinant collagen solution into a mold for forming, and lyophilizing it by a freeze-drying method with the following lyophilization parameters: -50°C . for 6 h, -30°C . for 2 h, -10°C . for 4 h, 0°C . for 2 h, 10°C . for 5 h, 20°C . for 20 h, 30°C . for 50 h;

[0085] (2) performing physical crosslinking with γ rays at a radiation dose of 35 kGy, and then performing chemical crosslinking with a 0.015 mol/L solution of glutaraldehyde (the mass ratio of glutaraldehyde to recombinant collagen was 1:4) at a reaction temperature of 25°C . for 1 h;

[0086] (3) washing in the washing device according to the present disclosure 9 times, with 10 minutes each time;

[0087] (4) freeze-drying the washed recombinant collagen sponge with the same lyophilization parameters as in the washing; encapsulating a sample thereof and sterilizing it with 25 kGy Co^{60} irradiation to obtain a recombinant collagen sponge material.

Test Experiments

1. Cell Proliferation Test on Recombinant Collagen Sponge Material

[0088] A sample material with an appropriate size (Example 1) was put in a well plate, and L929 cells growing in the exponential phase was inoculated onto the material placed in the well plate at a density of 2×10^5 cells. One hour later, 1 ml medium was supplemented to each well and the culturing was continued. After 20 hours, the material was gently rinsed with PBS 3 times and transferred into a new well, and the cell quantity was measured by a CCK-8 method. 1 ml of a medium containing 10% (volume fraction) CCK-8 reagent was added to each well. After incubation for 2 h in an incubator, the absorbance at 450 nm was measured with a microplate reader. In the proliferation test, after the cells were inoculated and cultured for 1 d, 3 d, 5 d, and 7 d, the number of cells was measured by the CCK-8 method, and the growth of the cells in the material was observed. The experimental results are shown in FIG. 3.

[0089] It can be seen from FIG. 3 that the cell quantity in the blank control group began to decrease after 3 days, and the cell quantity in the bovine collagen sponge control group began to decrease after 5 days. The test group showed an increasing trend from 1 to 7 days, indicating that the recombinant collagen sponge material can provide a more effective space and growth environment for cell proliferation, and has a good effect of guiding tissue repair.

2. Water Absorption Performance Test on Recombinant Collagen Sponge Material

[0090] The weight of the sample (Example 2) was measured as m_1 , and the weight after sufficient water absorption in physiological saline (10 s) was recorded as m_2 . According to the equation: Water absorption rate = $(m_2 - m_1) / m_1$, the water absorption rate of each sample was calculated. The results are shown in Table 1 below which shows a comparison of the water absorption rate between samples in two groups.

TABLE 1

Group	Water absorption rate
Control (Bovine collagen sponge)	22.6 ± 2.1
Test (The recombinant collagen sponge of Example 2)	$44.3 \pm 5.8^*$

[0091] It can be seen from Table 1 that the moisture absorption rate of the test group was significantly higher than that of the control group, and the difference was statistically significant ($P < 0.05$).

3. Hemostatic Performance Test on Recombinant Collagen Sponge Material

[0092] The evaluation was carried out by the liver hemostasis test in New Zealand rabbits. Specifically, a New Zealand rabbit was laparotomized layer by layer and the

liver was exposed. A 0.5 cm*1.0 cm bleeding wound was made on the liver lobe of the rabbit with a razor blade. The bleeding site was immediately subjected to hemostatic treatment with the recombinant collagen sponge or a natural collagen sponge, and the hemostatic effect and duration for local hemostasis were observed. After observation for a certain period of time, the hemostatic material was removed to observe whether the bleeding continued. The experimental results are shown in FIG. 4.

[0093] It can be seen from FIG. 4 that, as observed after 20 s hemostatic treatment with the control group (bovine collagen sponge) and the test group (recombinant collagen sponge) and removal of the material, the test group completely stopped bleeding, while the control group still showed bleeding and did not complete the hemostasis.

[0094] It can be known from the above measurement and evaluation results that the recombinant collagen sponge material prepared according to the present disclosure has good clinical effectiveness and can be applied to hemostasis and wound repair in the field of medical surgeries.

4. Wound Surface Repair Test on Recombinant Collagen Sponge Material

[0095] (1) Rats were allowed to adapt to the environment for one week after purchased to the laboratory.

[0096] (2) The rats were anesthetized and subjected to skin preparation, where intraperitoneal anesthetization was performed with 3% sodium pentobarbital at an anesthetic dose of 30 mg/kg, and after successful anesthesia, the back was shaved with an electric clipper.

[0097] (3) Three round full-thickness skin excision wounds having a diameter of 15 mm and an area of 1.766 cm² were created on the back of the animals with a modelling skin sampler (diameter 15 mm), and marked with Indian ink. The wounds were A, B, C, respectively corresponding to the group of the recombinant collagen sponge material of Example 1 (i.e., Material group A), the bovine collagen group (i.e., Control group B), and the blank control group (i.e., Blank group C). After the model was established, the wound was covered with the corresponding sponge and fixed with transparent waterproof medical tape (as shown in FIG. 5).

[0098] The wound surface repairing was observed for 3 to 18 days after the surgery, and the results are shown in FIG. 6 (the ordinate represents the relative value of the area of damaged skin, and the abscissa represents the postoperative recovery time). It can be seen from FIG. 6 that the wound surfaces in the three groups were all repaired and shrunk over time, wherein the recombinant collagen sponge material group was significantly better than the control group and the blank group, with statistical significance (P<0.05).

5. Validation Experiment on Recombinant Collagen Raw Material

[0099] The engineered *Pichia* strain according to the present disclosure was used to carry out large-scale biological fermentation to obtain the recombinant collagen raw material, and the sequence and molecular weight of the raw material protein were determined by N-terminal sequencing, amino acid analysis and mass spectrometry. The results are as follows.

1) N-Terminal Sequencing

[0100] The N-terminal sequence of the sample was determined by Edman degradation as: NH₂-Gly-Pro-Pro-Gly-Glu-Pro-Gly-Asn-Pro-Gly-Lys-Pro-Gly-Ser-Pro (shown in SEQ ID NO: 3), which is consistent with the designed sequence.

2) Amino Acid Analysis

[0101] It can be seen from FIG. 7 that the amino acid composition of the prepared sample was G, E, S, T, A, P, K, N, which are consistent with the designed amino acid composition.

3) Mass Spectroscopy

[0102] It can be seen from the mass spectrometry profile in FIG. 8 that the molecular weight of the sample was about 38 kDa, which is consistent with the designed value.

[0103] Conclusion: The prepared recombinant collagen is consistent with the designed requirements and is a 38 kDa recombinant collagen.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 3

<210> SEQ ID NO 1

<211> LENGTH: 1233

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Recombinant collagen polynucleotide

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(1233)

<400> SEQUENCE: 1

```

ggt cct ccc ggc gaa cca ggt aat cct ggt aaa cct ggt tct ccc ggc      48
Gly Pro Pro Gly Glu Pro Gly Asn Pro Gly Lys Pro Gly Ser Pro Gly
1           5           10           15

```

```

cca gct ggt tcc aac ggg gag ccg ggt cct gcc ggc tca ccc gga gaa      96
Pro Ala Gly Ser Asn Gly Glu Pro Gly Pro Ala Gly Ser Pro Gly Glu
20           25           30

```

-continued

aag ggg tcg caa ggt agt aat ggc aac cca gga ccg gca ggg aat cag Lys Gly Ser Gln Gly Ser Asn Gly Asn Pro Gly Pro Ala Gly Asn Gln 35 40 45	144
ggt caa cct ggc aac aaa gga agc ccc ggg aat cca ggt aag ccg ggc Gly Gln Pro Gly Asn Lys Gly Ser Pro Gly Asn Pro Gly Lys Pro Gly 50 55 60	192
gag cct gga tct aac ggg ccc cag ggt gaa cca ggc tcc caa gga aat Glu Pro Gly Ser Asn Gly Pro Gln Gly Glu Pro Gly Ser Gln Gly Asn 65 70 75 80	240
ccg ggg aaa aac ggt cag cct ggc tca ccc gga tcg caa ggg agt cca Pro Gly Lys Asn Gly Gln Pro Gly Ser Pro Gly Ser Gln Gly Ser Pro 85 90 95	288
ggt aat cag ggc caa ccg gga aag cct ggg cag ccc ggt gag caa ggc Gly Asn Gln Gly Gln Pro Gly Lys Pro Gly Gln Pro Gly Glu Gln Gly 100 105 110	336
agc cca gga aac cag ggg ccg gcg ggt aat gaa ggc cct aaa gga caa Ser Pro Gly Asn Gln Gly Pro Ala Gly Asn Glu Gly Pro Lys Gly Gln 115 120 125	384
ccc ggg cag aac ggt aag cca gga tcc ccg ggt cct ccc ggc gaa cca Pro Gly Gln Asn Gly Lys Pro Gly Ser Pro Gly Pro Pro Gly Glu Pro 130 135 140	432
ggt aat cct ggt aaa cct ggt tct ccc ggc cca gct ggt tcc aac ggg Gly Asn Pro Gly Lys Pro Gly Ser Pro Gly Pro Ala Gly Ser Asn Gly 145 150 155 160	480
gag ccg ggt cct gcc ggc tca ccc gga gaa aag ggg tcg caa ggt agt Glu Pro Gly Pro Ala Gly Ser Pro Gly Glu Lys Gly Ser Gln Gly Ser 165 170 175	528
aat ggc aac cca gga ccg gca ggg aat cag ggt caa cct ggc aac aaa Asn Gly Asn Pro Gly Pro Ala Gly Asn Gln Gly Gln Pro Gly Asn Lys 180 185 190	576
gga agc ccc ggg aat cca ggt aag ccg ggc gag cct gga tct aac ggg Gly Ser Pro Gly Asn Pro Gly Lys Pro Gly Glu Pro Gly Ser Asn Gly 195 200 205	624
ccc cag ggt gaa cca ggc tcc caa gga aat ccg ggg aaa aac ggt cag Pro Gln Gly Glu Pro Gly Ser Gln Gly Asn Pro Gly Lys Asn Gly Gln 210 215 220	672
cct ggc tca ccc gga tcg caa ggg agt cca ggt aat cag ggc caa ccg Pro Gly Ser Pro Gly Ser Gln Gly Ser Pro Gly Asn Gln Gly Gln Pro 225 230 235 240	720
gga aag cct ggg cag ccc ggt gag caa ggc agc cca gga aac cag ggg Gly Lys Pro Gly Gln Pro Gly Glu Gln Gly Ser Pro Gly Asn Gln Gly 245 250 255	768
ccg gcg ggt aat gaa ggc cct aaa gga caa ccc ggg cag aac ggt aag Pro Ala Gly Asn Glu Gly Pro Lys Gly Gln Pro Gly Gln Asn Gly Lys 260 265 270	816
cca ggt acc cca ggt cct ccc ggc gaa cca ggt aat cct ggt aaa cct Pro Gly Thr Pro Gly Pro Pro Gly Glu Pro Gly Asn Pro Gly Lys Pro 275 280 285	864
ggt tct ccc ggc cca gct ggt tcc aac ggg gag ccg ggt cct gcc ggc Gly Ser Pro Gly Pro Ala Gly Ser Asn Gly Glu Pro Gly Pro Ala Gly 290 295 300	912
tca ccc gga gaa aag ggg tcg caa ggt agt aat ggc aac cca gga ccg Ser Pro Gly Glu Lys Gly Ser Gln Gly Ser Asn Gly Asn Pro Gly Pro 305 310 315 320	960
gca ggg aat cag ggt caa cct ggc aac aaa gga agc ccc ggg aat cca Ala Gly Asn Gln Gly Gln Pro Gly Asn Lys Gly Ser Pro Gly Asn Pro 325 330 335	1008

-continued

```

ggt aag ccg ggc gag cct gga tct aac ggg ccc cag ggt gaa cca ggc      1056
Gly Lys Pro Gly Glu Pro Gly Ser Asn Gly Pro Gln Gly Glu Pro Gly
          340                      345                      350

tcc caa gga aat ccg ggg aaa aac ggt cag cct ggc tca ccc gga tcg      1104
Ser Gln Gly Asn Pro Gly Lys Asn Gly Gln Pro Gly Ser Pro Gly Ser
          355                      360                      365

caa ggg agt cca ggt aat cag ggc caa ccg gga aag cct ggg cag ccc      1152
Gln Gly Ser Pro Gly Asn Gln Gly Gln Pro Gly Lys Pro Gly Gln Pro
          370                      375                      380

ggt gag caa ggc agc cca gga aac cag ggg ccg gcg ggt aat gaa ggc      1200
Gly Glu Gln Gly Ser Pro Gly Asn Gln Gly Pro Ala Gly Asn Glu Gly
          385                      390                      395                      400

cct aaa gga caa ccc ggg cag aac ggt aag cca      1233
Pro Lys Gly Gln Pro Gly Gln Asn Gly Lys Pro
          405                      410
    
```

```

<210> SEQ ID NO 2
<211> LENGTH: 411
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Construct
    
```

```

<400> SEQUENCE: 2

Gly Pro Pro Gly Glu Pro Gly Asn Pro Gly Lys Pro Gly Ser Pro Gly
1          5          10          15

Pro Ala Gly Ser Asn Gly Glu Pro Gly Pro Ala Gly Ser Pro Gly Glu
          20          25          30

Lys Gly Ser Gln Gly Ser Asn Gly Asn Pro Gly Pro Ala Gly Asn Gln
          35          40          45

Gly Gln Pro Gly Asn Lys Gly Ser Pro Gly Asn Pro Gly Lys Pro Gly
          50          55          60

Glu Pro Gly Ser Asn Gly Pro Gln Gly Glu Pro Gly Ser Gln Gly Asn
          65          70          75          80

Pro Gly Lys Asn Gly Gln Pro Gly Ser Pro Gly Ser Gln Gly Ser Pro
          85          90          95

Gly Asn Gln Gly Gln Pro Gly Lys Pro Gly Gln Pro Gly Glu Gln Gly
          100          105          110

Ser Pro Gly Asn Gln Gly Pro Ala Gly Asn Glu Gly Pro Lys Gly Gln
          115          120          125

Pro Gly Gln Asn Gly Lys Pro Gly Ser Pro Gly Pro Pro Gly Glu Pro
          130          135          140

Gly Asn Pro Gly Lys Pro Gly Ser Pro Gly Pro Ala Gly Ser Asn Gly
          145          150          155          160

Glu Pro Gly Pro Ala Gly Ser Pro Gly Glu Lys Gly Ser Gln Gly Ser
          165          170          175

Asn Gly Asn Pro Gly Pro Ala Gly Asn Gln Gly Gln Pro Gly Asn Lys
          180          185          190

Gly Ser Pro Gly Asn Pro Gly Lys Pro Gly Glu Pro Gly Ser Asn Gly
          195          200          205

Pro Gln Gly Glu Pro Gly Ser Gln Gly Asn Pro Gly Lys Asn Gly Gln
          210          215          220

Pro Gly Ser Pro Gly Ser Gln Gly Ser Pro Gly Asn Gln Gly Gln Pro
          225          230          235          240
    
```

-continued

Gly Lys Pro Gly Gln Pro Gly Glu Gln Gly Ser Pro Gly Asn Gln Gly
245 250 255

Pro Ala Gly Asn Glu Gly Pro Lys Gly Gln Pro Gly Gln Asn Gly Lys
260 265 270

Pro Gly Thr Pro Gly Pro Pro Gly Glu Pro Gly Asn Pro Gly Lys Pro
275 280 285

Gly Ser Pro Gly Pro Ala Gly Ser Asn Gly Glu Pro Gly Pro Ala Gly
290 295 300

Ser Pro Gly Glu Lys Gly Ser Gln Gly Ser Asn Gly Asn Pro Gly Pro
305 310 315 320

Ala Gly Asn Gln Gly Gln Pro Gly Asn Lys Gly Ser Pro Gly Asn Pro
325 330 335

Gly Lys Pro Gly Glu Pro Gly Ser Asn Gly Pro Gln Gly Glu Pro Gly
340 345 350

Ser Gln Gly Asn Pro Gly Lys Asn Gly Gln Pro Gly Ser Pro Gly Ser
355 360 365

Gln Gly Ser Pro Gly Asn Gln Gly Gln Pro Gly Lys Pro Gly Gln Pro
370 375 380

Gly Glu Gln Gly Ser Pro Gly Asn Gln Gly Pro Ala Gly Asn Glu Gly
385 390 395 400

Pro Lys Gly Gln Pro Gly Gln Asn Gly Lys Pro
405 410

<210> SEQ ID NO 3
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: For recombinant collagen validation
<400> SEQUENCE: 3

Gly Pro Pro Gly Glu Pro Gly Asn Pro Gly Lys Pro Gly Ser Pro
1 5 10 15

What is claimed is:

1. A recombinant collagen, comprising:
 - (a) a protein composed of the amino acid sequence represented by SEQ ID NO: 2; and/or
 - (b) a protein which has the same function as (a) and is derived from (a) by substitution, deletion and/or addition of one or more amino acids in SEQ ID NO:2.
2. The recombinant collagen according to claim 1, wherein the DNA sequence of the polynucleotide encoding the amino acid sequence represented by SEQ ID NO: 2 comprises the DNA sequence represented by SEQ ID NO:1.
3. An engineered *Pichia* strain deposited with the accession number of CGMCC No. 19314, for use in fermentation to obtain the recombinant collagen according to claim 1.
4. A recombinant collagen sponge material, obtained by sequential physical cross-linking and chemical cross-linking of the recombinant collagen according to claim 1; wherein the recombinant collagen sponge material has a moisture absorption capacity of 40-50, and porosity of 90% or higher.
5. A method for preparing the recombinant collagen sponge material according to claim 4, comprising the following steps:
 - dissolving the recombinant collagen according to claim 1 in water to obtain a recombinant collagen solution;

lyophilizing the recombinant collagen solution by a freeze-drying method; and

subjecting the lyophilized and formed recombinant collagen to physical cross-linking and chemical cross-linking in sequence, to obtain the recombinant collagen sponge material.

6. The method according to claim 5, wherein the recombinant collagen sponge material obtained after the cross-linkings is further subjected to washing, drying, and sterilization.

7. The method according to claim 6, wherein the device used for the washing includes a rotating rod and a porous clamp box fixed on the rotating rod; wherein the porous clamp box is used to hold the recombined collagen sponge, and the rotating rod is used to rotate and drive the porous clamp box to flip in a cleaning medium, so as to wash off residual reagents in the recombinant collagen sponge material.

8. The method according to claim 6, wherein the drying includes one or more of oven drying, freeze drying, and vacuum drying.

9. The method according to claim 6, wherein the sterilization is performed by 15 to 25 kGy Co⁶⁰ irradiation.

10. The method according to claim **5**, wherein the physical crosslinking includes one or more of thermal crosslinking, radiation crosslinking, and repeated freezing-reconstitution.

11. The method according to claim **5**, wherein the temperature for thermal crosslinking is 110° C., and the crosslinking duration is 2 h.

12. The method according to claim **5**, wherein the chemical crosslinking is performed by addition of a chemical crosslinking agent including one or more of glutaraldehyde, carbodiimide, and genipin.

13. The method according to claim **5**, wherein the concentration of a chemical crosslinking agent is 0.005 to 0.015 mol/L.

14. The method according to claim **5**, wherein the concentration of the recombinant collagen solution is 1% to 5%.

15. The method according to claim **5**, further comprising injecting the recombinant collagen solution into a mold for forming before the recombinant collagen solution is subjected to freeze-drying.

16. The method according to claim **11**, wherein the radiation source for the radiation cross-linking includes ultraviolet rays and/or gamma rays.

17. The method according to claim **13**, wherein the mass ratio of the chemical crosslinking agent to the recombinant collagen is 1:1 to 5.

18. The method according to claim **13**, wherein the chemical crosslinking duration is 1 to 5 hours.

19. The method according to claim **15**, wherein the recombinant collagen solution is freeze-dried at a gradient from -50° C. to 30° C.

* * * * *